These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23318290)

  • 1. ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?
    Gillardon F; Kremmer E; Froehlich T; Ueffing M; Hengerer B; Gloeckner CJ
    J Neurosci Methods; 2013 Mar; 214(1):62-8. PubMed ID: 23318290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.
    Reichling LJ; Riddle SM
    Biochem Biophys Res Commun; 2009 Jun; 384(2):255-8. PubMed ID: 19397894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.
    Liu Z; Galemmo RA; Fraser KB; Moehle MS; Sen S; Volpicelli-Daley LA; DeLucas LJ; Ross LJ; Valiyaveettil J; Moukha-Chafiq O; Pathak AK; Ananthan S; Kezar H; White EL; Gupta V; Maddry JA; Suto MJ; West AB
    J Biol Chem; 2014 Nov; 289(47):32937-51. PubMed ID: 25228699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.
    Deng X; Dzamko N; Prescott A; Davies P; Liu Q; Yang Q; Lee JD; Patricelli MP; Nomanbhoy TK; Alessi DR; Gray NS
    Nat Chem Biol; 2011 Apr; 7(4):203-5. PubMed ID: 21378983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
    Henderson JL; Kormos BL; Hayward MM; Coffman KJ; Jasti J; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD; Galatsis P
    J Med Chem; 2015 Jan; 58(1):419-32. PubMed ID: 25353650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
    Dzamko N; Deak M; Hentati F; Reith AD; Prescott AR; Alessi DR; Nichols RJ
    Biochem J; 2010 Sep; 430(3):405-13. PubMed ID: 20659021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
    Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
    Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.
    Nichols RJ; Dzamko N; Hutti JE; Cantley LC; Deak M; Moran J; Bamborough P; Reith AD; Alessi DR
    Biochem J; 2009 Oct; 424(1):47-60. PubMed ID: 19740074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the autophosphorylation sites of LRRK2.
    Kamikawaji S; Ito G; Iwatsubo T
    Biochemistry; 2009 Nov; 48(46):10963-75. PubMed ID: 19824698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X; Choi HG; Buhrlage SJ; Gray NS
    Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
    Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
    J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.
    Liu M; Bender SA; Cuny GD; Sherman W; Glicksman M; Ray SS
    Biochemistry; 2013 Mar; 52(10):1725-36. PubMed ID: 23379419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression, purification and preliminary biochemical and structural characterization of the leucine rich repeat namesake domain of leucine rich repeat kinase 2.
    Vancraenenbroeck R; Lobbestael E; Weeks SD; Strelkov SV; Baekelandt V; Taymans JM; De Maeyer M
    Biochim Biophys Acta; 2012 Mar; 1824(3):450-60. PubMed ID: 22251894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation.
    Kamikawaji S; Ito G; Sano T; Iwatsubo T
    Biochemistry; 2013 Sep; 52(35):6052-62. PubMed ID: 23924436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease.
    Koshibu K; van Asperen J; Gerets H; Garcia-Ladona J; Lorthioir O; Courade JP
    Pharmacology; 2015; 96(5-6):240-7. PubMed ID: 26382237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A continuous and direct assay to monitor leucine-rich repeat kinase 2 activity.
    Silva RG; Geoghegan KF; Qiu X; Aulabaugh A
    Anal Biochem; 2014 Apr; 450():63-9. PubMed ID: 24463014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.
    Liu M; Dobson B; Glicksman MA; Yue Z; Stein RL
    Biochemistry; 2010 Mar; 49(9):2008-17. PubMed ID: 20146535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity.
    Ray S; Bender S; Kang S; Lin R; Glicksman MA; Liu M
    J Biol Chem; 2014 May; 289(19):13042-53. PubMed ID: 24695735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation of LRRK2: from kinase to substrate.
    Lobbestael E; Baekelandt V; Taymans JM
    Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.